Final terms for Medivir’s voluntary redemption programme
Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the board of directors now has set the final terms for Medivir’s voluntary redemption programme. Every seventh share will be redeemable for a cash consideration of SEK 140 per share.
The shareholders will receive one redemption right for each share held in Medivir. Seven redemption rights entitle to redemption of one share held. In total, a maximum amount of SEK 625,200,380 may be paid as proceeds for the redeemed shares.
The voluntary redemption programme, comprising a reduction of the statutory reserve, a reduction of the share capital for repayment to the shareholders and a bonus issue without issuance of new shares, was resolved on at the extraordinary general meeting in Medivir on 20 November 2014.
Below are the dates for the redemption programme. An information brochure with additional information about the voluntary redemption programme is available as from Monday 2 February 2015 on the company’s website, www.medivir.se.
|3 February 2015||Last day of trading in Medivir shares including the right to receive redemption rights|
|5 February 2015||Record day for receiving redemption rights|
|6 February 2015||Distribution of the information brochure and the application form to the company's directly registered shareholders commences|
|10 February – 24 February 2015||Application period for redemption|
|10 February – 20 February 2015||Period for trading in redemption rights|
|10 February – 18 February 2015||Application period for commission-free sale of a maximum of 1,000 redemption rights|
|27 February – 6 March 2015||Period for trading in redemption shares|
|Around 17 March 2015||Payment of redemption proceeds|
For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292.
Ola Burmark, newly appointed Chief Financial Officer Medivir AB, mobile +46 (0)725 480580.
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 8.30 CET on 30 January 2015.
Medivir is an emerging and profitable research‐based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. Medivir receives royalties from Johnson & Johnson on the global sales of the hepatitis C pharmaceutical, OLYSIO®. In addition, revenues for sales of OLYSIO in the Nordic region are generated through the company’s own sales and marketing organisation. Medivir’s research and development portfolio of pharmaceuticals is based on the company’s expertise within protease inhibitor design and nucleoside/nucleotide science. The company’s research and development focus is within infectious diseases and oncology and the on-going clinical projects in osteoarthritis and neuropathic pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.